methotrexate

Topical therapies (glucocorticosteroids, a betamethasone-calcipotriol combination or calcineurin inhibitors) remain the first-line therapy for mild to moderate cases. Patients with severe scalp psoriasis and those who do not respond to topical treatment are candidates for systemic therapy, including targeted therapy (interleukin-17 inhibitors, interleukin-23 inhibitors, tumor necrosis alpha inhibitors) or classic treatment (methotrexate, cyclosporine) Recent studies have demonstrated promising outcomes with novel treatments including Janus kinase (JAK) inhibitors and other new small molecules. This review provides updated information focused on diagnostic methods and targeted treatment of scalp psoriasis with relevance to clinical management of patients.

After removal of the IUD and methotrexate therapy for presumed ectopic pregnancy in an unknown location, β-HCG level remained elevated...Hormone therapy with oral estradiol 2 mg daily and cyclic oral micronized progesterone 200 mg on 12 days of each month was initiated...After pregnancy has been ruled out, less common causes of β-HCG elevations like gestational trophoblastic disease, germ cell tumors, POI associated menopause, and heterophile antibody interference, should be evaluated. FXPOI should be considered in young patients with β-HCG elevation.

CS-QT-PCL-MTX-Ns at a concentration of 120 μg/mL at 72 h which was 14 ± 2.0% exhibited dose dependent cytotoxicity against MCF-7 breast cancer cells with PDI < 0.5. Conclusively, CH-Qt-PCL-MTX-Ns demonstrate promising potential for the management of breast cancer along with enhanced anti-inflammatory effect.

P1, N=47, Recruiting, National Cancer Institute (NCI) | Trial completion date: May 2026 --> Apr 2027 | Trial primary completion date: May 2026 --> Apr 2027

MALAT1 and NEAT1 were overexpressed and identified as lncRNA hubs, whereas H19 displayed a dual expression pattern, overexpressed in sensitive cells 48 h post-MTX exposure but underexpressed in resistant cells. Our findings support the involvement of these lncRNAs and CAV1 in the early transcriptional response to MTX in colorectal cancer cells.

A patient with biopsy-proven VRL underwent longitudinal vitreous cytokine analysis during intravitreal methotrexate (MTX) and dexamethasone (DEX) therapy. Co-expression of IL-10 and IL-May 16, reflect a dynamic interaction between lymphoma cells and the TME, contributing to immune modulation and treatment resistance. Longitudinal IL-16 monitoring may provide additional insight into disease activity and therapeutic response; however, this requires validation in larger VRL cohorts, ideally including inflammatory controls.

The patient was successfully treated with intravitreal methotrexate and systemic chemotherapy followed by consolidative low-dose radiotherapy...Extended latency periods between central nervous system involvement and ocular manifestations are possible, potentially longer than previously reported. CSF analysis for MYD88 mutation and IL-10/IL-6 ratio provides crucial diagnostic value when vitreous sampling is inconclusive, emphasizing the importance of multi-parametric liquid biopsy approaches in challenging VRL cases.

Multivariate analysis identified CD83 IHC high expression as an independent predictor of non-SR cases. High CD83 expression is an independent prognostic factor in MTX-associated IDD-DLBCL, and combined evaluation may refine risk stratification and guide clinical decisions.

In elderly PCNSL patients, R-MPV without routine WBRT provides effective disease control while being associated with less structural brain change. CSF IL-10 may represent a potential biomarker of susceptibility to treatment-related brain structural alterations.

Therefore, this work aimed to evaluate the potential effect of enzymatically-modified isoquercitrin (EMIQ, 50 and 100 mg/kg body weight "b.wt", administered orally for 8 days), in comparison with methotrexate (MTX, a synthetic drug), against imiquimod (IMQ)-induced psoriatic lesions in female BALB/c mice. Moreover, oral administration of EMIQ prevented significantly (P < 0.001) the vascular permeability associated with augmented Evans blue leakage and dermal accumulation of degranulated mast cells, suggesting a reduction in inflammation and edema. Taken together, our study demonstrated that EMIQ can alleviate psoriasis and may be considered as a promising strategy for psoriasis treatment via targeting IL-23/IL-17A axis and mast cell degranulation.

P3, N=9350, Active, not recruiting, Children's Oncology Group | Trial completion date: Mar 2028 --> Mar 2026

P2, N=222, Recruiting, National Cancer Institute (NCI) | Phase classification: P3 --> P2